文献速递慢病管理老年与多病共存

SGLT2抑制剂处方差距:为何初级保健错失良机?

The SGLT2 inhibitor gap: why are we missing opportunities in primary care?
PubMed 文献 · Br J Gen Pract · 2026-05-14

本文综述英国处方数据、全国调查和定性研究,探讨全科医生对SGLT2抑制剂处方不足的障碍。尽管指南推荐用于2型糖尿病合并心肾疾病及所有症状性心衰或CKD患者,但处方仍不一致,合并心血管疾病者反而更少用药。障碍涉及处方者、患者和系统层面,需加强证据传播和处方信心。

要点

  • SGLT2抑制剂已成心肾疾病和心衰基石治疗,但英国初级保健处方率仍低。
  • 合并心血管疾病患者接受SGLT2抑制剂比例(9.8%)低于无心血管疾病者(13.8%)。
  • 障碍包括处方者不熟悉、担心副作用、治疗惰性、患者多药共存及系统限制。

核心结论

  • SGLT2抑制剂是常见初级保健疾病循证管理的核心,需缩小证据与实践差距。

研究设计与样本

  • 综述英国近期处方数据、全国调查及探讨全科医生观点的定性研究。

主要发现

  • 尽管指南认可,SGLT2抑制剂处方仍不一致。
  • 合并心血管疾病患者接受SGLT2抑制剂的比例为9.8%,低于无心血管疾病者的13.8%。
  • 障碍涉及处方者、患者和系统三个层面。

关键数值与推荐

  • NICE推荐2型糖尿病合并心肾疾病者使用SGLT2抑制剂。
  • NICE推荐所有症状性心衰或CKD患者使用SGLT2抑制剂,不论糖尿病状态。

临床怎么用

  • 全科医生应熟悉SGLT2抑制剂证据,克服治疗惰性,主动为符合条件者处方。
  • 需加强试验数据传播,提升处方信心,并优化系统支持结构。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have evolved from glucose-lowering agents to cornerstone therapies for cardiovascular disease (CVD), chronic kidney disease (CKD), and heart failure (HF). The National Institute for Health and Care Excellence now recommends their use in people with type 2 diabetes and cardiorenal disease, and for all with symptomatic HF or CKD, irrespective of diabetes status. Despite this, uptake in UK primary care remains low. AIM: The aim was to explore barriers contributing to the under-prescription of SGLT2 inhibitors in UK general practice. METHOD: Recent UK prescribing data, national surveys, and qualitative studies examining GP perspectives on SGLT2 inhibitors were reviewed. RESULTS: Despite guideline endorsement, prescribing remains inconsistent. Paradoxically, patients with CVD are less likely to receive an SGLT2 inhibitor (9.8%) than those without (13.8%). Barriers were identified at prescriber, patient, and system levels. Prescribers cited unfamiliarity with newer agents, concerns about adverse effects, difficulty keeping pace with emerging evidence, and therapeutic inertia when HbA1c appears 'controlled'. Access to specialist input also influenced behaviour - where endocrinology support is accessible, initiation is often deferred. Patient-related factors included polypharmacy, perceived side effects, and low motivation. System-level barriers such as restrictive formularies and prescribing budgets further limited uptake. CONCLUSION: SGLT2 inhibitors are now central to evidence-based management of common primary care conditions. Closing this evidence-practice gap requires better dissemination of trial data, enhanced prescriber confidence, and supportive health system structures.

来源:Br J Gen Pract,查看原文。版权归原作者所有。

引用

  1. Ng CJW, McNamara P. The SGLT2 inhibitor gap: why are we missing opportunities in primary care? Br J Gen Pract. 2026. PMID: 42134923. doi:10.3399/bjgp26X745437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。